Responsible Business Performance Report 2024
GSK plc Pharmaceutical industry company
Download
Abstract: Our purpose is to unite science, technology and talent to get ahead of disease together and positively impact the health of billions of people. Being a responsible business is an integral part of our strategy and culture, supporting our business performance and long-term growth. It helps us build trust with our stakeholders, reduce risk, help people to thrive and to deliver health impact at scale. To deliver on our purpose, we need to consider our impacts, risks and opportunities across everything we do ? in our business and value chain. Six focus areas help us to address what is most material to our business and most important to our stakeholders. They are: ? Access to healthcare ? Global health and health security ? Environment ? Inclusion and diversity ? Ethical standards ? Product governance Being responsive to the environment in which we operate and the changing expectations of our key stakeholders is critical to building trust. With that in mind, we continue to review and evolve the actions we are taking in all of our six areas. Specifically for inclusion and diversity, we are presently working to understand and evaluate the impact of the legal environment. We are progressing this work and reviewing activities, with the following principles in mind: ? Firstly, as ever, we will always comply with the law and be respectful of the environment in which we operate. ? Secondly, we remain fully committed to equal employment opportunity, non-discrimination, and merit-based decisionmaking in the way we recruit, manage and develop our people. ? And thirdly, we continue to believe that an inclusive culture, with different perspectives and experiences, helps drive superior business performance and deliver better health outcomes for patients. We periodically undertake materiality assessments to assess key issues (see our 2022 assessment on gsk.com). In 2024, we undertook a double materiality assessment in preparation for reporting against the Corporate Sustainability Reporting Directive to inform our reporting for the financial year 2025, to be published in 2026. gsk.com: Our materiality assessment Our contribution to the UN SDGs The 17 SDGs set out a vision for ending poverty, hunger and inequality, and protecting the planet?s natural resources, by 2030. Our six focus areas are where we can most effectively contribute to meeting the SDGs. As a global biopharma company, we can make the most significant contribution to SDG3: Good Health and Wellb